BioKey reported third-quarter license fee revenue of $1.28 million, up 39%, lifting gross margin to 90%. It retired remaining note debt, won a Central Bank of Jordan initiative, and targets profitability with roughly $1.2 million in first-quarter license renewals.
BKYI · Bio Key International Inc · Documents
Substantial doubt about the company's ability to continue as a going concern.
“In accordance with ASU *No.* *2014*-*15,* "Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic *205*-*40*)", the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within *one* year after the date that the consolidated financial statements are issued. The history of losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
BIO-KEY INTERNATIONAL, INC. reported nine-month revenue of 5,548,305, net loss of 1,667,972 and operating cash outflow of 2,634,682. Management said substantial doubt exists about its ability to continue as a going concern.
BIO-key reported Q3’26 license fee revenue growth of 39%, gross margin improvement to 90%, and an 8% narrowing of net loss to $(886K). Nine-month revenue rose 14% to $5.5M, working capital reached $3.1M, and the company retired its remaining note.
On October 30, 2026, Bio Key International, Inc. stockholders approved issuing up to 1,236,668 common shares upon exercise of warrants issued in the August 10, 2026 warrant inducement transaction.
BIO-key registered resale of up to 1,236,668 common shares issuable upon warrant exercise by Armistice Capital Master Fund Ltd.; full cash exercise would provide approximately $5,020,872.08, while sale proceeds go to the selling stockholder.
BIO-key International, Inc. registered the resale of up to 1,236,668 shares issuable upon warrant exercise. Warrants have a $4.06 exercise price, require stockholder approval, and would generate $5,020,872.08 in gross proceeds if exercised for cash.
BIO-KEY INTERNATIONAL, INC. stockholders approved board elections, ratification of M&K CPAs, PLLC, and advisory executive compensation; voting remains open on approval of up to 1,236,668 shares upon warrant exercise, with the meeting reconvening October 30, 2026.
Bio Key International Inc stockholders approved Proposals 1, 2 and 3 on October 2, 2026 and adjourned consideration of Proposal 4, which seeks approval to issue up to 1,236,668 common shares upon exercise of warrants.
BIO-key International, Inc. entered four Exchange Agreements with Streeterville Capital, LLC on September 29, 2026, exchanging four partitioned promissory notes totaling $416,315.80 for 247,805 common shares, fully paying the Original Note.